Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This research concludes that finasteride significantly reduces dihydrotestosterone levels and prostate size in men with BPH and may improve urinary symptoms, with greater baseline prostate size predicting more pronounced benefits compared to placebo.

This study found that electroosmotic flow through hair follicles significantly contributes to solution flow during iontophoresis in hairless mouse skin.

This paper discusses risk factors and prevention strategies for acute urinary retention secondary to benign prostatic hyperplasia, emphasizing the role of PSA levels and the benefits of medications like finasteride and alpha-blockers, but reports no new clinical results.

This study found that combining dibenyline and finasteride for symptomatic BPH treatment offered modest improvements with fewer additional side effects compared to each drug alone.

Men with early balding may have a higher risk of prostate issues, and surgery for prostate cancer has a slight survival benefit over radiation.

This study found that dutasteride significantly reduces the risk of acute urinary retention and surgical intervention in men with benign prostatic enlargement compared to placebo.

This study found that 5-alpha-reductase inhibitor monotherapy for symptomatic benign prostatic hyperplasia showed some clinical benefit over placebo but was linked to a higher incidence of sexual side effects.

In this study, a 12-week treatment with Angelicae Gigantis Radix and Glycyrrhizae Radix complex was well tolerated and showed therapeutic effects on moderate lower urinary tract symptoms in men.

This study found that men with early-onset androgenetic alopecia had significantly larger prostate volumes and lower urinary flow rates compared to healthy controls, suggesting a possible link between AGA and prostate-related urinary symptoms.

This review found that finasteride monotherapy for managing LUTS/BPH significantly reduced prostate volume and improved symptoms, with sexual dysfunctions reported as notable side effects compared to placebo, but emphasizes the need for more comprehensive studies.

This study found that men with early-onset androgenetic alopecia had larger prostate volumes and lower urinary flow rates compared to those without the condition, suggesting a potential link between AGA and urinary symptoms.

This study reports on biofeedback treatment for dysfunctional voiding in three adult cases, providing insights into this condition when diagnosed beyond childhood.

Early balding may be a sign of future prostate problems.

Researchers created a simple tool to predict bladder blockage from prostate enlargement using urine flow rate and prostate volume.

In this study, men with benign prostatic hyperplasia who took finasteride for four years experienced reduced urinary symptoms, fewer surgeries, less acute urinary retention, increased urinary flow rates, and decreased prostate volume.

This review summarizes a meta-analysis suggesting that finasteride is most effective for improving symptoms and urinary flow in men with large prostates experiencing benign prostatic hyperplasia.

This study explores the clinical significance of the intravesical prostatic protrusion/prostate volume ratio in diagnosing bladder outlet obstruction but reports no new results.

This study demonstrated that 12 months of 5 mg daily finasteride treatment reduced prostate volume, dihydrotestosterone, and prostate-specific antigen levels, while improving urinary flow rates and symptom scores in benign prostatic hyperplasia patients.

This study aimed to identify characteristics of patients who fail to void during pressure-flow studies, which limits the determination of the cause behind their lower urinary tract symptoms.

This study found that after 12 months of treatment with 5 mg of finasteride, patients with benign prostatic hyperplasia showed reduced prostate volume, DHT and PSA levels, and improved urinary flow rates and symptoms.

This study found that dutasteride improved maximum urinary flow rate more effectively than finasteride when used in combination therapy with tamsulosin for treating benign prostatic hyperplasia over six months.

This review provides a comprehensive overview of the mechanisms, efficacy, and adverse reactions of drugs commonly used for treating benign prostatic hyperplasia but reports no new clinical results.

This study found that Thermobalancing therapy using Dr Allen's Device significantly improved symptoms and quality of life in men with benign prostatic hyperplasia, but larger prostate sizes may require longer treatment.

Combination therapy improves urinary flow and reduces residual urine, but needs better stent design.

This study found that dutasteride was more effective than finasteride in reducing total prostate volume and PSA levels and improving symptoms in patients with benign prostate hyperplasia.

This study found that one year of finasteride treatment significantly reduced PSA levels and prostate volume in men with elevated PSA and negative prior biopsy, potentially aiding prostate cancer diagnosis.

This study reported that cognitive biopsy diagnosed prostate cancer in 44% of patients with at least one previous negative biopsy, with higher detection rates in lesions classified as PI-RADS 4 and 5.

This review summarizes existing studies on 5-alpha reductase inhibitors, noting their effectiveness in reducing prostate volume and cancer risk but highlighting an increased risk of higher grade prostate cancer.

This review reports that combination therapy with 5α-reductase inhibitors and α1-receptor blockers does not appear to benefit patients with benign prostatic hyperplasia and prostate volumes up to 40–45 ml, but may be more effective for larger prostate volumes.

This study found that combination therapy with alpha-adrenergic blockers and 5α-reductase inhibitors significantly improved urinary symptoms, reduced prostate volume, and decreased the risk of acute urinary retention and postoperative surgery in patients with benign prostatic hyperplasia compared to monotherapy.